Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Insights into the success and failure of systemic therapy for hepatocellular carcinoma
Jordi Bruix, Leonardo Gomes da Fonseca, María Reig
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 16, Iss. 10, pp. 617-630
Closed Access | Times Cited: 177

Showing 1-25 of 177 citing articles:

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
Robin Kate Kelley, Bruno Sangro, William Proctor Harris, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 27, pp. 2991-3001
Open Access | Times Cited: 371
Systemic treatment of hepatocellular carcinoma: An EASL position paper
Jordi Bruix, Stephen L. Chan, Peter R. Galle, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 4, pp. 960-974
Closed Access | Times Cited: 303
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
Shukui Qin, Feng Bi, Shanzhi Gu, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 27, pp. 3002-3011
Open Access | Times Cited: 295
Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy
Alessandro Vitale, Franco Trevisani, Fabio Farinati, et al.
Hepatology (2020) Vol. 72, Iss. 6, pp. 2206-2218
Closed Access | Times Cited: 147
Breakthroughs in Hepatocellular Carcinoma Therapies
Amit G. Singal, Masatoshi Kudo, Jordi Bruix
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2135-2149
Open Access | Times Cited: 82
Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation
Neda Yahoo, Michael Dudek, Percy A. Knolle, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 538-551
Open Access | Times Cited: 68
Ferroptosis‐Enhanced Immunotherapy with an Injectable Dextran‐Chitosan Hydrogel for the Treatment of Malignant Ascites in Hepatocellular Carcinoma
Jingshu Meng, Xiao Yang, Jing Huang, et al.
Advanced Science (2023) Vol. 10, Iss. 20
Open Access | Times Cited: 54
Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice
Giuseppe Cabibbo, Ciro Celsa, Lorenza Rimassa, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 6, pp. 957-966
Open Access | Times Cited: 24
Local and Regional Therapies for Hepatocellular Carcinoma
Roman Kloeckner, Peter R. Galle, Jordi Bruix
Hepatology (2020) Vol. 73, Iss. S1, pp. 137-149
Closed Access | Times Cited: 108
Evolving role of regorafenib for the treatment of advanced cancers
Axel Grothey, Jean‐Yves Blay, Nick Pavlakis, et al.
Cancer Treatment Reviews (2020) Vol. 86, pp. 101993-101993
Open Access | Times Cited: 86
Activation of YAP1 by N6-Methyladenosine–Modified circCPSF6 Drives Malignancy in Hepatocellular Carcinoma
Yunhao Chen, Zhenan Ling, Xianlei Cai, et al.
Cancer Research (2021) Vol. 82, Iss. 4, pp. 599-614
Open Access | Times Cited: 84
The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma
Zhongqiang Zhang, Xiao Tan, Jing Luo, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 10
Open Access | Times Cited: 80
The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?
Ester Gonzalez‐Sanchez, Javier Vaquero, Maite G. Fernández‐Barrena, et al.
Cancers (2021) Vol. 13, Iss. 13, pp. 3248-3248
Open Access | Times Cited: 62
Exosomal hsa_circ_0004658 derived from RBPJ overexpressed-macrophages inhibits hepatocellular carcinoma progression via miR-499b-5p/JAM3
Lei Zhang, Jing Zhang, Pengfei Li, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 52
Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook
Yinjie Fan, Hang Xue, Hua‐chuan Zheng
Journal of Hepatocellular Carcinoma (2022) Vol. Volume 9, pp. 233-263
Open Access | Times Cited: 46
Minimally Invasive Delivery of Percutaneous Ablation Agent via Magnetic Colloidal Hydrogel Injection for Treatment of Hepatocellular Carcinoma
Wenshu Wu, Xu Yan, Sheng Chen, et al.
Advanced Materials (2024) Vol. 36, Iss. 26
Closed Access | Times Cited: 15
CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5‐LSD1‐NF‐κB oncogenic signaling
Bo Hu, Yang Xu, Yuancheng Li, et al.
Clinical and Translational Medicine (2020) Vol. 10, Iss. 8
Open Access | Times Cited: 67
Epithelial–Mesenchymal Transition (EMT) Induced by TGF-β in Hepatocellular Carcinoma Cells Reprograms Lipid Metabolism
Jitka Soukupová, Andrea Malfettone, Esther Bertrán, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5543-5543
Open Access | Times Cited: 53
MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis
Ting Yu, Jiajian Yu, Lu Lu, et al.
Cellular Oncology (2021) Vol. 44, Iss. 4, pp. 821-834
Open Access | Times Cited: 49
Diagnóstico y tratamiento del carcinoma hepatocelular. Actualización del documento de consenso de la AEEH, AEC, SEOM, SERAM, SERVEI y SETH
María Reig, Alejandro Forner, Matías A. Ávila, et al.
Medicina Clínica (2021) Vol. 156, Iss. 9, pp. 463.e1-463.e30
Open Access | Times Cited: 43
Nanotechnology for Hepatocellular Carcinoma: From Surveillance, Diagnosis to Management
Han Wu, Ming‐Da Wang, Lei Liang, et al.
Small (2021) Vol. 17, Iss. 6
Closed Access | Times Cited: 42
2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis
Banglun Pan, Zhanfei Chen, Xiaoxia Zhang, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 6, pp. e006817-e006817
Open Access | Times Cited: 22
Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis
Ismael El Hajra, Marco Sanduzzi‐Zamparelli, Víctor Sapena, et al.
Hepatology (2023) Vol. 77, Iss. 4, pp. 1139-1149
Closed Access | Times Cited: 21
Development and validation of a CTNNB1‐associated metabolic prognostic model for hepatocellular carcinoma
Junyu Huo, Liqun Wu, Yunjin Zang
Journal of Cellular and Molecular Medicine (2020) Vol. 25, Iss. 2, pp. 1151-1165
Open Access | Times Cited: 46
Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma
Leonardo Gomes da Fonseca, María Reig, Jordi Bruix
Clinics in Liver Disease (2020) Vol. 24, Iss. 4, pp. 719-737
Closed Access | Times Cited: 44
Page 1 - Next Page

Scroll to top